Drugs / OZEKIBART
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03715933 | Oct 2018 → Dec 2028 expected | Ewing sarcoma, colorectal adenocarcinoma | Inhibrx Biosciences, Inc | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04950075 | Sep 2021 → Sep 2025 overdue | chondrosarcoma | Inhibrx Biosciences, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OZEKIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314613 ↗ |
| Known as | INBRX-109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04950075 ↗ |
| Action | Activate | “INBRX-109, a third-generation death receptor 5 (DR5) agonist” PMID 37265425 ↗ Aug 2023 |
| Modality | Monoclonal antibody | — CHEMBL5314613 ↗ |
| Route | Intravenous | “IV every three weeks” NCT04950075 ↗ |